Using companion and coupled diagnostics within strategy to personalize targeted medicines

Personalized Medicine

Volumn 9, Issue 7, 2012, Pages 751-761

  Singer, Donald R J ^a   Watkins, John ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

companion diagnostic; companion therapeutic; coupled diagnostics; health economics; pharmacogenetics

Indexed keywords

ABACAVIR; AZATHIOPRINE; B RAF KINASE; BCR ABL PROTEIN; CARBAMAZEPINE; CETUXIMAB; CHEMOKINE RECEPTOR CCR5; CLOPIDOGREL; CRIZOTINIB; CYTOCHROME P450 2C19; DASATINIB; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETRETIN; FIRTECAN; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; IRINOTECAN; K RAS PROTEIN; MARAVIROC; MERCAPTOPURINE; NILOTINIB; PACLITAXEL; PANITUMUMAB; STEM CELL FACTOR; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB;

ALLERGIC REACTION; ANAPLASTIC LYMPHOMA; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; BIOTECHNOLOGY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CHROMOSOME 22; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPANION DIAGNOSTIC; COMPANION THERAPEUTICS; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; COUNSELING; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG DESIGN; DRUG LABELING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; FETUS DISEASE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GENE DOSAGE; GENE MUTATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH EDUCATION; HEALTH SERVICE; HEART FAILURE; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICAL PROCEDURES; MELANOMA; MOLECULAR DIAGNOSIS; PATIENT SAFETY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREGNANCY TEST; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TEST; STEVENS JOHNSON SYNDROME; STOMACH ADENOCARCINOMA; STOMACH CANCER; TERATOGENICITY; THERANOSTIC; TOXIC EPIDERMAL NECROLYSIS; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84866367424     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.86     Document Type: Review

References (55)

1. Lukianova-Hleb EY, Oginsky AO, Samaniego AP et al. Tunable plasmonic nanoprobes for theranostics of prostate cancer. Theranostics 1, 3-17 (2011).
2. Crabb N, Marlow M, Bell H, Newland A. The NICE Diagnostics Assessment Programme. Health Policy and Technology 1(1), 5-7 (2012).
3. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004).
4. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum. Mutat. 32(5), 526-531 (2011).
5. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
6. Gijsen M, King P, Perera T et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 8(12), e1000563 (2010).
7. Connelly PA, Stern DF. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proc. Natl Acad. Sci. USA 87(16), 6054-6057 (1990).
8. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011).
9. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J. Clin. Oncol. 17(1), 434 (1999).
10. Quintás-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 113(8), 1619-1630 (2009).
11. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006).
12. Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat. Rev. Clin. Oncol. 9(6), 351-358 (2012).
13. Bennett L, Zhao Z, Barber B et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first-or second-line treatment. Br. J. Cancer 105(10), 1495-1502 (2011).
14. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
15. Mack GS. FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 27(2), 110-112 (2009).
16. Argiles G, Dienstmann R, Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 8(4), 373-389 (2012).
17. Bokemeyer C, Cutsem EV, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48(10), 1466-1475 (2012).
18. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF-and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum. Pathol. 36(5), 486-493 (2005).
19. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
20. Yang H, Higgins B, Kolinsky K et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72(3), 779-789 (2012).
21. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat. Rev. Drug Discov. 10(12), 897-898 (2011).
22. Perner S, Wagner PL, Demichelis F et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10(3), 298-302 (2008).
23. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
24. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
25. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359(14), 1429-1441 (2008).
26. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr. Clin. Pharmacol. 1(1), 119-128 (2006).
27. Biason P, Masier S, Toffoli G. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J. Chemother. 20(2), 158-165 (2008).
28. Avery PJ, Jorgensen A, Hamberg AK et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin. Pharmacol. Ther. 90(5), 701-706 (2011).
29. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 87(5-6), 274-285 (2011).
30. Mehta TY, Prajapati LM, Mittal B et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75(6), 579-582 (2009).
31. Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf. 25(12), 885-892 (2002).
32. Agarwal A. Do companion diagnostics make economic sense for drug developers? N. Biotechnol. doi:10.1016/j.nbt.2012.04.004 (2012) (Epub ahead of print).
33. Davis JC, Furstenthal L, Desai AA et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8(4), 279-286 (2009).
34. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J. Natl Compr. Canc. Netw. 9(12), 1335-1341 (2011).
35. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8), 1211-1221 (2006).
36. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer 106(6), 1100-1106 (2012).
37. DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nat. Rev. Drug Discov. 10(1), 23-27 (2011).
38. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336(7653), 1114-1117 (2008). .Websites
39. US FDA: in vitro companion diagnostic devices. www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm (Accessed 28 May 2012)
40. Commentary on 2003 US FDA guidance on diagnostic devices. http://goliath.ecnext.com/coms2/gi-0199-1303851/Unprecedented-Dx-Rx-Summit- Unites.html (Accessed 28 May 2012)
41. Draft guidance for industry and US FDA staff: in vitro companion diagnostic devices. www.fda.gov/medicaldevices/deviceregulationandguidance/ guidancedocuments/ucm262292.htm (Accessed 28 May 2012)
42. US FDA: current good manufacturing practice for combination products (draft guidance). www.fda.gov/RegulatoryInformation/Guidances/ucm126198.htm (Accessed 28 May 2012)
43. NICE guidelines for trastuzumab: breast cancer: TA34. www.nice.org.uk/TA34 (Accessed 31 May 2012)
44. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. www.nice.org.uk/TA107 (Accessed 31 May 2012)
45. US FDA and trastuzumab. www.cancer.gov/cancertopics/druginfo/fda- trastuzumab (Accessed 31 May 2012)
46. FDA and c-KIT approval. www.fda.gov/medicaldevices/ productsandmedicalprocedures/deviceapprovalsandclearances/recently- approveddevices/ucm080911.htm (Accessed 31 May 2012)
47. Health Canada authorization of panitumumab with conditions. www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/vectibix-dhcpl-lapds- 105601-eng.php (Accessed 29 May 2012)
48. US FDA approves vemurafenib and companion diagnostic BRAF test for late-stage skin cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2011/ ucm268241.htm (Accessed 31 May 2012)
49. US FDA approves crizotinib with companion diagnostic for a type of late-stage lung cancer. Second targeted therapy approved with a test this year. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm (Accessed 31 May 2012)
50. NICE approval of companion diagnostic for gefitinib. http://guidance. nice.org.uk/TA/Wave10/21/FAD/FinalAppraisalDetermination/pdf/English (Accessed 31 May 2012)
51. FDA Maraviroc approval. www.guidelines.gov/content.aspx?id=35093 (Accessed 31 May 2012)
52. FDA approves two fixed-dose combination drug products for the treatment of HIV-1 infection. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ ucm108335.htm (Accessed 15 August 2012)
53. Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm124718.htm (Accessed 6 June 2012)
54. Drug Price Competition and Patent Term Restoration Act (Hatch Waxman Act). http://kenyon.com/Resources/Hatchman/HTMLHelp/!SSL!/WebHelp/hatchman/ Contents.htm (Accessed 8 August 2012)
55. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007). http://medicine.iupui.edu/ clinpharm/ddis/table.aspx (Accessed 1 June 2012)